- Home
- CAAP vs EWTX Comparison
CAAP vs EWTX Comparison
Compare CAAP & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CAAP | EWTX |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | Luxembourg | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 4.3B |
| IPO Year | 2017 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CAAP | EWTX |
|---|---|---|
| Price | $23.81 | $38.46 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | $32.40 | ★ $54.00 |
| AVG Volume (30 Days) | 261.4K | ★ 1.2M |
| Earning Date | 11-23-2026 | 11-13-2026 |
| Dividend Yield | ★ 7.67% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.51 | N/A |
| Revenue Next Year | $9.22 | N/A |
| P/E Ratio | $26.35 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $21.54 | $16.70 |
| 52 Week High | $30.50 | $48.51 |
Technical Indicators
Market Signals| Indicator | CAAP | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 44.74 | 43.36 |
| Support Level | $23.65 | $37.33 |
| Resistance Level | $26.06 | $41.13 |
| Average True Range (ATR) | 0.91 | 1.83 |
| MACD | -0.11 | 0.18 |
| Stochastic Oscillator | 32.01 | 44.67 |
Price Performance
Historical ComparisonAbout CAAP Corporacion America Airports SA
Corporacion America Airports SA acquires, develops, and operates airport concessions. Its operating segments are geographically divided into Argentina, Italy, Brazil, Uruguay, Ecuador, and Armenia. The company generates a majority of its revenue from the Argentina segment. The firm's revenue is categorized into Aeronautical Revenue, Non-Aeronautical Revenue, Commercial Revenue, Construction Service Revenue, and Other Revenue.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.